BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 9, 2006
View Archived Issues
In Huntington's, Are Inclusion Bodies Answer, Not Problem?
Read More
Neuromed's $25M To Fuel Calcium Channel Research
Read More
Alexza Prices IPO At $44M To Finance Clinical Work
Read More
Clinical Roundup
Read More
Other News To Note
Read More
FDA Committee Advocates Tysabri's Return To Market
GAITHERSBURG, Md. - Members of an FDA advisory committee voted unanimously in favor of bringing Tysabri (natalizumab) back to the multiple sclerosis market, but with restrictions. (BioWorld Today)
Read More
Neurocrine Dropping APL-MS Work After Missed Endpoint
Read More